Plain-English translation of NCT07541781 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a medication normally used for diabetes, to see if it can help your immune system better fight a recurring grade 4 brain tumor (glioblastoma). You would take alongside , a standard treatment you may already be receiving. The goal is to learn whether this medication is safe and can reduce immune cells that actually help tumors hide from your body's defenses.
When glioblastoma comes back after initial treatment, it becomes harder to treat. Recent research suggests that certain immune cells called myeloid-derived suppressor cells actually help tumors survive and grow. This trial exists to see if blocking these cells with this medication could give standard treatments a better chance of working.
You likely qualify if…
You likely don't qualify if…
The trial has two parts. First, researchers will give you the medication in combination with to find the safest dose. In the second part, you'll take the medication for at least 5 days before surgery to remove your tumor, then continue taking it afterward along with . During the trial, you'll have blood tests and imaging scans to monitor how you're doing, and if you're in the surgical part, your removed tumor tissue will be studied to see if the medication changed the immune cells inside it.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Kailin Yang, MD, PhD
Enrollment target
~45 participants
Started
June 2026
Primary completion
June 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kailin Yang, MD, PhD
University of Iowa
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.